|
Evaluation of Treated and Untreated Stroke Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Evaluation of Treated and Untreated Stroke conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Evaluation of Treated and Untreated Stroke Clinical research trials and Evaluation of Treated and Untreated Stroke health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Evaluation of Treated and Untreated Stroke. Evaluation of Treated and Untreated Stroke Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Evaluation of Treated and Untreated Stroke clinical trial. Human subjects often get the best healthcare available for their Evaluation of Treated and Untreated Stroke condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of Treated and Untreated Stroke  Evaluation of Treated and Untreated Stroke
Evaluation of Treated and Untreated Stroke
For Condition: Cerebrovascular Accident,Infarction,Ischemia
Status: Completed
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: This project will investigate the evolution of treated and untreated stroke in patients recruited from the collaborative brain stroke program between NINDS, CC, and Suburban Hospital. The study will use anatomical and functional imaging techniques with emphasis on the acute and subacute stage (less than one month) of the disease. As the availability of new therapeutic options for the management of acute brain stroke increases, the need to define the evolution of the disease becomes paramount, particularly as therapeutic windows, defined by known and perhaps yet undiscovered parameters, may exist. Defining these parameters will be based on state-of-the-art imaging technology with the potential of clarifying the division between ischemia (reversible damage) and infarction (irreversible). Measures of lesion size and distribution along with vascular morphology, diffusion, perfusion, flow-related, and metabolic measures will be obtained over time. We foresee these measurements will significantly develop our understanding of cerebral ischemia and introduce diagnostic and quantitative tools to guide therapy and measure its efficacy.
Details: This project will investigate the evolution of treated and untreated stroke in patients recruited from the collaborative brain stroke program between NINDS, CC, and Suburban Hospital. The study will use anatomical and functional imaging techniques with emphasis on the acute and subacute stage (less than one month) of the disease. As the availability of new therapeutic options for the management of acute brain stroke increases, the need to define the evolution of the disease becomes paramount, particularly as therapeutic windows, defined by known and perhaps yet undiscovered parameters, may exist. Defining these parameters will be based on state-of-the-art imaging technology with the potential of clarifying the division between ischemia (reversible damage) and infarction (irreversible). Measures of lesion size and distribution along with vascular morphology, diffusion, perfusion, flow-related, and metabolic measures will be obtained over time. We foresee these measurements will significantly improve our understanding of cerebral ischemia and introduce diagnostic and quantitative tools to guide therapy and measure its efficacy.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Any subject suspected of having a stroke based on the NIH Stroke Scale and age 21 years or over. Subjects will be enrolled into this protocol only if they are determined intellectually capable of providing their own informed consent. No subjects will be included if they have a condition which would preclude their entry into the scanner (e.g., paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.) or present unnecessary risks (e.g., surgery of uncertain type, symptoms of pheochromocytoma or insulinoma, etc.). No women who are pregnant or lactating. No subjects with hemoglobinopathies and asthma. No subjects with renal or hepatic disease. No subjects who have a contraindication to MR scanning such as surgery that involves metal clips or wires which might be expected to concentrate radiofrequency fields or cause tissue damage from twisting in a magnetic field (e.g., aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker or autodefibrillator, cochlear implant, ocular foreign body and mechanical pump).
Total Enrollment: 100
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990041; 99-CC-0041
Study Start Date: February 10, 1999
Record last reviewed: January 9, 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001840
Other Infarction Studies:
1. A Phase III study for the prevention of autogenous vein graft failure in peripheral artery bypass procedures
2. A safety and efficacy study of HGF via plasmid vector to improve perfusion in critical limb ischemia.
3. Evaluation of Treated and Untreated Stroke
Related Studies:
Other Infarction Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Evaluation of Treated and Untreated Stroke
|
|
|
|
|
|
|
|
